OR WAIT 15 SECS
© 2020 MJH Life Sciences and BioPharm International. All rights reserved.
August 02, 2020
Many antibody-drug conjugate therapies are in the pipeline; only a handful have been approved. What are the bottlenecks?
July 21, 2020
Preliminary data from a German Phase I/II trial shows Pfizer/BioNTech COVID-19 vaccine candidate produces immune response.
Study reports immune and T-cell response from CanSino COVID-19 vaccine candidate.
July 20, 2020
Strong immune response by patients receiving two doses of vaccine suggests a possible treatment strategy.
July 08, 2020
VAR2 Pharmaceuticals has been selected for its development of a drug-conjugated malaria protein that potentially selectively binds to most human tumor types.
BARDA and DOD have awarded a $450-million contract to Regeneron Pharmaceuticals to manufacture and supply an investigational double antibody cocktail in development for treating COVID-19.
July 02, 2020
RNA is easier to manipulate than DNA but challenging to deliver to the right cells.
July 01, 2020
Data and science must guide FDA in making pressure-filled COVID-19 vaccine and therapy approval decisions.
The complete response letter was issued for a biologics license application for Abicipar pegol, an investigational treatment for wet age-related macular degeneration, based on FDA’s determination of an unfavorable benefit–risk ratio.
June 11, 2020
The companies have entered into a development and manufacturing agreement for Anthos Therapeutics’ abelacimab for treating thrombotic disorders.